Richard Gill, CFA, reviews three companies he thinks could contribute significantly to both your ISA dividend income and capital growth over the next few years.
A developer of best-in-class targeted therapeutics has had its near- clinic ready TYK2/JAK 1 inhibitor programme earmarked as a potential therapy for severe Covid-19.
Some pharmaceutical companies have managed to develop a coronavirus vaccine in record time, while others have given up.
Richard Gill, CFA, reviews When the Fund Stops, the untold story behind the downfall of Neil Woodford, Britain’s most successful fund manager.
There are a few sectors and themes that will be hot during 2021 and that promise some good returns, writes Filipe R. Costa.
The pound came into this year trading at its best levels against the US dollar since April 2018 – so just where are the opportunities in this market in the year ahead?
Michael Taylor reviews three companies that he believes could be primed for success in the months ahead.
As we enter a new year Richard Gill, CFA, reviews the UK small cap markets and provides a few investment ideas for the next 12 months.
Richard Gill, CFA, reviews The Smart Money Method, where author Stephen Clapham provides investors with the insider stock picking techniques used by top hedge funds.
Will Britain really be better positioned to prosper going forward under the new trade deal? Only time will tell, writes Victor Hill.